Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Indian Journal of Forensic Medicine & Toxicology
Rana M Hameed
Unknown Affiliation
Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Aflatoxin B1 as a Threshold Concept of Uncertain Etiology of Chronic Kidney Diseases Sada Abdullah Kareem; Rana M Hameed; Sami Abd AL-Redha; Hassanein Al-Khatt
Indian Journal of Forensic Medicine & Toxicology Vol. 15 No. 3 (2021): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v15i3.15399

Abstract

A case control study was conducted in karbala province to investigate aflatoxin B1 (AFB1) exposure among the chronic kidney disease (CKD) patients and healthy control. AFB1 level were measured qualitatively by Thin layer chromatography and quantitatively by high-performance liquid chromatography.The assessment of positive AFB1 samples were evaluated along with biomarkers of renal functions tests.The results showed that the investigated population were exposed to Aflatoxins. AFB1 was detected in 100% of uncertain CKD patients and 24%, 20% in certain CKD patients and healthy control respectively. The concentration ranges in serum samples were 0.68 –8.33 ng/mL for uncertain CKD patients, 1.21-5.60 ng/mL for certain CKD patients and 0.11- 1.30 ng/mL for healthy control. The un-certain etiology of CKD patients had a significant associations of decreasing GFR and increasing the levels of urea, creatinine with positive serum AFB1. This association was also highly interest with regard to potential interactions with Urea levels in the control group. The measurement of the AFB1 in serum samples of CKD patients and healthy control were indicated a long term exposure to the toxin which result in uncertain etiology of CKD. The effect of AFB1 exposure was confirmed through the assessment of the biochemical marker of renal tests. This study can be a good establish of a national AFs exposure monitoring programs. Also the study highlighted the needing to identify the pathogenesis of contribution AFB1 in the increasing number of uncertain CKD patients. Future study is encouraged to focus on broader areas which cover the whole of country.
The Intrasubject Variability in the Acute Phase Protein (Orosomucoid) Levels and their Influenced by Breast Malignancy Shatha Abd Al-jabbar; Rana M Hameed; Wesen Adel Mehdi
Indian Journal of Forensic Medicine & Toxicology Vol. 15 No. 3 (2021): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v15i3.15400

Abstract

Background: The major healthcare burden is breast cancer, screening services are expensive and difficult to organize, requiring major issues of administrative and quality control. however a potential biomarker that could help in the screening of the disease progress might improve the available routine mode of diagnosis. This study was aimed to examine the variability of Orosomucoid levels in breast cancer patients also to review the background documents on the state of the art of the scientific literature in this area of work.Materials and Methods: A cross sectional study was conduct on a breast cancer patients which were collected from oncology unit , Al-Hussein teaching Hospital in Kerbala / Iraq. Enzyme Linked Immunosorbent Assay system (ELISA) was performed using Sandwich method to measure the concentrations of serum Orosomucoid protein levels. Results: The primary stage of breast cancer was shown a wide spread range of the protein levels ( 95.4- 664.5 ng/ml) compared to the metastasis stage range (59.0- 376.3 ng/ml). The effect of disease duration and drug therapy also examine. Long term of duration of the disease with chemotherapy and/or hormonal therapy might decrease the level of protein, but, no significant differences were found.Conclusion: Since rosomucoid protein works as transporter, the protein may be used as an indication of the drug response due to decreased level in patients who were taking both chemotherapy and hormone therapy. Determination of serum rosomucoid protein could guide treating oncologist to have an idea to what extent the patients have response.
Co-Authors Hassanein Al-Khatt Sada Abdullah Kareem Sami Abd AL-Redha Shatha Abd Al-jabbar Wesen Adel Mehdi